Autonomix Medical's Novel Nerve Neurolysis Tech Garners Top Abstract, Podium Presentation at Major Medical Conference
AMIX sits 20% above its 52-week low of $0.342 on light trading volume (0.1× avg).
Summary
Autonomix Medical's novel transvascular peripheral RF nerve neurolysis technique has been selected as a "Top Abstract" and for a podium presentation at the Cardiovascular Research Technologies (CRT) 2026 Meeting. This recognition provides significant external validation for the company's core platform technology, which is crucial given its severe financial challenges, including a going concern warning and short cash runway, as noted in its recent 10-Q. For a micro-cap company with financial distress, this scientific validation at a leading interventional cardiovascular medicine forum is a material positive development, enhancing credibility and visibility. This builds on previous positive clinical data reported in January for pancreatic cancer pain treatment, further highlighting the broader applicability of their technology. Investors will be watching for the actual presentation on March 7th for further details on the clinical feasibility and outcomes.
At the time of this announcement, AMIX was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.34 to $2.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.